CIDRAP newsletters options
Late last week in Emerging Infectious Diseases, South Korean researchers reported that average time from exposure to COVID-19 diagnosis was 3.7 days in quarantined close contacts of patients infected by the SARS-CoV-2 Omicron variant and that 99.1% of diagnoses occurred by day 10, supporting a 10-day quarantine.
A large North Carolina study finds no elevated risk in kids and teens who have asthma.
In the US, a new study on Pfizer vaccine effectiveness in kids shows solid 2-dose COVID-19 protection.
Data show 4 months of antituberculosis treatment non-inferior to the standard 6-month treatment.
The global COVID death toll is closer to 18.2 million through 2021, with wide regional variations, data indicate.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Venatorx Pharmaceuticals of Malvern, Pennsylvania, yesterday released promising data from a phase 3 trial of its investigational new drug for patients with complicated urinary tract infections (cUTIs).
The Centers for Disease Control and Prevention (CDC) said COVID-19 vaccine uptake among children 5 to 11 years old in the United States remained low during the first 11 weeks of vaccine eligibility, especially in high social vulnerability index (SVI) areas. The research was published today in Morbidity and Mortality Weekly Report (MMWR).
The absolute difference between an antiseptic drug and antibiotics has limited clinical significance.
In the US, lawmakers scramble to find funding for COVID-19 activities.
Delaware, Maryland, and Missouri report new highly pathogenic avian flu outbreaks.
Protection against hospital illness was 85% for 2 doses against Alpha and Delta and 86% for 3 doses against Omicron.
A study of children 3 years old or younger who were hospitalized for uncomplicated community-associated pneumonia (CAP) found that a significant proportion did well without a full course of antibiotics, researchers reported yesterday in Open Forum Infectious Diseases.
While Medicare beneficiary hospitalizations for non–COVID-19 diagnoses fell sharply in March and April 2020 and stayed low through September 2021, death rates after hospitalization rose substantially—particularly for Black and Hispanic patients, finds a study yesterday in JAMA Network Open.
"These findings imply that the pandemic may substantially contribute to the world dementia burden."
The United States continues to report the most COVID-19 fatalities of any country.
Continuing the corticosteroid dexamethasone after hospital release didn't benefit COVID-19 patients who didn't complete the 10-day drug regimen during their stay, finds a study published yesterday in JAMA Network Open.
The imaging differences between COVID-19 and non-COVID patients were modest, about 2%.
Fully 92% of side effects during the first 6 months of the US vaccine rollout were mild and short-lived.
Different approaches may be needed in the future, experts say, such as vaccines that target a specific variant.
